Mometamax®

Pharmaceutical Name
Gentamicin Sulfate, USP, Mometasone Furoate Monohydrate and Clotrimazole, USP Otic Suspension

Finally, Once-a-day Treatment You Can Count On¹

• Convenient SID dosing regardless of otitis externa severity²
• As few as 4 drops required at administration²
• Easier for clients, less stressful for dogs than BID
• Helps promote client compliance to ensure treatment success

True Once-a-day Convenience and Truly Outstanding Efficacy
Controlled study confirms ...
Significant symptom resolution after 7 days of treatment¹

Triple formulation includes a new generation of veterinary steroid

Mometasone furoate -

• Extensively proven in adult and pediatric human dermatology and allergy¹
• Highly effective relief from atopy, a primary precipitant of otitis externa

Advanced formulation for true once-a-day efficacyMometasone Furoate - A new generation veterinary steroid

• 7.7 times more potent than betamethasone¹
• Safety profile comparable to betamethasone¹
• No corticosteroid-related side effects observed in canine clinical trials¹

• Clotrimazole - The #1 otic antifungal¹

• Superior antifungal potency to Nystatin®* confirmed in a recent national study^±3

• Gentamicin - Broad-spectrum antibacterial power²
  • Highly active against gram-positive and gram-negative bacteria
  • Resistance remains low - 13% for Pseudomonas, the most common bacterial isolate^§1
  • Bacterial action at low concentrations decreases the potential for recurrence¹

• Solution-like consistency for clear advantages
  • Ensures prolonged contact at the site of infection⁴
  • Colorless solution is easy to differentiate from exudate
  • Eliminates staining
  • Hydrocarbon formulation consistency facilitates easy counting of drops for proper dosing

• Convenient dosing
  • Only 4 drops (dogs<30 lbs) or 8 drops (dogs> or =30 lbs)

Components may cause local hypersensitivity or ototoxity. For side effects and warnings, please see accompanying full Product Label.

* Nystatin is a registered trademark of DSM Anti-Infectives.
±National Veterinary School of Nantes, France.
±±Solid media.
§Overall, in a study of 1500 dogs.
1 Data on file, Schering-Plough Animal Health Corporation.
2 Mometamax® full Product Information
3 Bourdeau P, Marchand AM, Etoré F. In vitro activity of posaconazole and other antifungals against Malassezia pachydermatis isolated from dogs. Poster presented at: 5th World Congress of Veterinary Dermatology; August 25-28, 2004: Vienna, Austria. Poster P-17.
4 Riviere JE, Spoo JW. Dermatopharmacology. In: Adams R, ed. Veterinary Pharmacology and Therapeutics. 8th ed. Ames, Iowa: Iowa State University Press; 2001; 53:1084-1104.

Dosage
For further information including dose rate and complete directions and warnings, please see the Product Label by clicking here.

Mometamax® is a registered trademark of Schering-Plough Animal Health Corporation.